Anti-diabetes effect of Zn(II)/carnitine complex by oral administration

Chemical and Pharmaceutical Bulletin

Volumn 51, Issue 2, 2003, Pages 230-231

  Yoshikawa, Yutaka ^a   Ueda, Eriko ^a   Sakurai, Hiromu ^b   Kojima, Yoshitane ^a  

^a Osaka Prefecture University   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Glucose tolerance test; Hypoglycemic effect; L carnitine; Oral administration; Type 2 diabetes; Zinc(II) complex

Indexed keywords

CARNITINE DERIVATIVE; ZINC COMPLEX; ANTIDIABETIC AGENT; CARNITINE; CHLORIDE; ZINC CHLORIDE; ZINC DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; GLUCOSE BLOOD LEVEL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; ORAL DRUG ADMINISTRATION; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CARNITINE; CHLORIDES; HYPOGLYCEMIC AGENTS; MICE; ZINC COMPOUNDS;

EID: 0043023404     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.51.230     Document Type: Article

References (21)

1. Sakurai H., Kojima Y., Yoshikawa Y., Kawabe K., Yasui H., Coord. Chem. Rev., 226, 187-198 (2002).
2. Yoshikawa Y., Ueda E., Kawabe K., Miyake H., Sakurai H., Kojima Y., Chem. Lett., 2000, 874-875 (2000).
3. Ueda E., Yoshikawa Y., Kishimoto N., Tadokoro M., Yanagihara N., Sakurai H., Kojima Y., Chem. Lett., 2001, 1184-1185 (2001).
4. Yoshikawa Y., Ueda E., Miyake H., Sakurai H., Kojima Y., Biochem. Biophys. Res. Commun., 281, 1190-1193 (2001).
5. Yoshikawa Y., Ueda E., Suzuki Y., Yanagihara N., Sakurai H., Kojima Y., Chem. Pharm. Bull., 49, 652-654 (2001).
6. Yoshikawa Y., Ueda E., Kawabe K., Miyake H., Takino T., Sakurai H., Kojima Y., J. Biol. Inorg. Chem., 7, 68-73 (2002).
7. Ueda E., Yoshikawa Y., Ishino Y., Sakurai H., Kojima Y., Chem. Pharm. Bull., 50, 337-340 (2002).
8. Bremer J., Physiol. Rev., 63, 1420-1480 (1983).
9. Lai H. S., Chen Y., Chen W. J., World J. Surg., 22, 42-46 (1998).
10. Redouche C. J., Seim H., Ann. Rev. Nutr., 18, 39-61 (1998).
11. Satoh S., Ryoikibetsu Shokogun Shirizu, 18 Pt1, 398-400 (1998).
12. Matsuda K., Yuasa H., Watanabe J., Biol. Pharm. Bull., 21, 752-755 (1998).
13. Jeukendrup A. E., Ann. N.Y. Acad. Sci., 967, 217-235 (2002).
14. Koudelova J., Mourek J., Drahota Z., Rauchova H., Physiol. Res., 43, 387-389 (1994).
15. Mindell E., "Supplement Bible," Simon & Schuster, New York, 1998, pp. 193-194.
16. Arockia Rani P. J., Panneerselvam C., Exp. Gerontol., 36, 1713-1726 (2001).
17. Mindell E., "Supplement Bible," Simon & Schuster, New York, 1998, pp. 85-86.
18. Nakai M., Watanabe H., Fujisawa C., Kakegawa H., Satoh T., Takada J., Matsushita R., Sakurai H., Biol. Pharm. Bull., 18, 719-725 (1995).
19. -4 M epinephrine was then added to the reaction mixtures and the result solutions were incubated at 37°C for 180 min. The reactions were stopped by soaking in ice water and the mixtures were centrifuged at 3000 rpm for 10 min. For outer solution of the cells, FFA levels were determined with an FFA kit (Wako).
20. Song M. K., Rosenthal M. J., Naliboff B. D., Phanumas L., Kang K. W., Metabolism, 47, 39-43 (1998).
21. Shisheva A., Gefel D., Schechter Y., Diabetes, 41, 982-988 (1992).